<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37567514</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-3064</ISSN><JournalIssue CitedMedium="Internet"><Volume>218</Volume><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Respiratory medicine</Title><ISOAbbreviation>Respir Med</ISOAbbreviation></Journal><ArticleTitle>Asthma in the era of COVID-19.</ArticleTitle><Pagination><StartPage>107373</StartPage><MedlinePgn>107373</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rmed.2023.107373</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0954-6111(23)00261-5</ELocationID><Abstract><AbstractText>Since its global invasion in 2019, COVID-19 has affected several aspects of patients' lives and posed a significant impact on the health care system. Several patient populations were identified to be at high risk of contracting SARS-CoV-2 infection and/or developing severe COVID-19-related sequelae. Conversely, anyone who has contracted SARS-CoV-2 is at risk to experience symptoms and signs consistent with post-COVID manifestations. Patients with asthma were initially thought to be at increased risk and severity for SARS-CoV-2 infection. However, accumulating evidence demonstrates that asthma endotypes/phenotypes and comorbidities influence the risk stratification in this population. Furthermore, initial concerns about the potentially increased risk of poor outcomes with asthma treatments such as inhaled corticosteroids and biologics have not been substantiated. In this review, we provide an update on COVID-19 and asthma, including risk of susceptibility, clinical manifestations and course in this population as well as discuss recommendations for management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Assaf</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Pulmonary and Critical Care Medicine, University of New Mexico, Albuquerque, NM, USA. Electronic address: SAssaf@salud.unm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stenberg</LastName><ForeName>Henning</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Primary Health Care Research, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jesenak</LastName><ForeName>Milos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departments of Pulmonology and Phthisiology and Paediatrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Department of Clinical Immunology and Allergology, University Teaching Hospital in Martin, Martin, Slovak Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarasevych</LastName><ForeName>Svitlana P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Zaans Medical Center, Zaandam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanania</LastName><ForeName>Nicola A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamant</LastName><ForeName>Zuzana</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Dept of Microbiology Immunology &amp; Transplantation, KU Leuven, Catholic University of Leuven, Belgium; Dept of Respiratory Medicine &amp; Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden; Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic; Dept Clin Pharm &amp; Pharmacol, Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. Electronic address: z.diamant@4gems.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Respir Med</MedlineTA><NlmUniqueID>8908438</NlmUniqueID><ISSNLinking>0954-6111</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asthma</Keyword><Keyword MajorTopicYN="N">Biologicals</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Phenotypes</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: SA: Her institution received research support on her behalf as site PI for a GSK clinical trialHS: No COIs related to this workMJ: ALK, Stallergenes-Greer, Chiesi, GSK, Pfizer, Novartis, AstraZeneca and SANOFISPT: No COIs related to this workNAH: Received honoraria for serving as advisor or consultant for GSK, AstraZeneca, Sanofi, Regeneron, Amgen, Genentech, Novartis and Teva. His institution received research grant support of his behalf from GSK, Genentech, Sanofi, Teva, Novartis, and AstraZenecaZD: received consultancy fees/lecture fees/fees for attending advisory boards from ALK, Antabio, Foresee Pharmaceuticals, GlaxoSmithKline, Hippo-Dx, QPS-Netherlands, Sanofi-Genzyme; she served as Director Respiratory &amp; Allergy at QPS-NL and this CRO received research grants for clinical trials from HAL Allergy, Janssen Research &amp; Development LLC, Patara pharma, Cerbios, Merck Sharp &amp; Dohme, Novartis, Foresee Pharmaceuticals and ERA4TB (IMI-project).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>12</Day><Hour>10</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37567514</ArticleId><ArticleId IdType="doi">10.1016/j.rmed.2023.107373</ArticleId><ArticleId IdType="pii">S0954-6111(23)00261-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>